{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:26:51Z","timestamp":1786750011648,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"DOI":"10.7759\/cureus.114549","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:38:55Z","timestamp":1786747135000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of De Novo Neuroendocrine Prostate Cancer Presenting With Elevated Carcinoembryonic Antigen (CEA) Levels"],"prefix":"10.7759","author":[{"given":"Shunsuke","family":"Tazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.04.006","article-title":"Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis","volume":"15","author":"Zaffuto E","year":"2017","unstructured":"Zaffuto E, Pompe R, Zanaty M, et al.. Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clin Genitourin Cancer. 2017, 15:e793-800. 10.1016\/j.clgc.2017.04.006","journal-title":"Clin Genitourin Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1508410","article-title":"A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review","volume":"15","author":"Han W","year":"2025","unstructured":"Han W, Rexiati N, Yu F, et al.. A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review. Front Oncol. 2025, 15:1508410. 10.3389\/fonc.2025.1508410","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein JI","year":"2014","unstructured":"Epstein JI, Amin MB, Beltran H, et al.. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014, 38:756-67. 10.1097\/PAS.0000000000000208","journal-title":"Am J Surg Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7888\/juoeh.46.23","article-title":"Treatment outcomes of second-line systemic therapy for neuroendocrine prostate cancer: a report of four cases","volume":"46","author":"Tsubonuma Y","year":"2024","unstructured":"Tsubonuma Y, Funakoshi K, Takaba T, et al.. Treatment outcomes of second-line systemic therapy for neuroendocrine prostate cancer: a report of four cases. J UOEH. 2024, 46:23-8. 10.7888\/juoeh.46.23","journal-title":"J UOEH"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi K","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, et al.. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019, 20:686-700. 10.1016\/S1470-2045(19)30082-8","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong AJ","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al.. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019, 37:2974-86. 10.1200\/JCO.19.00799","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.11.005","article-title":"Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study","volume":"8","author":"Santoni M","year":"2025","unstructured":"Santoni M, B\u00fcttner T, Rescigno P, et al.. Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study. Eur Urol Oncol. 2025, 8:444-51. 10.1016\/j.euo.2024.11.005","journal-title":"Eur Urol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal R","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, et al.. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018, 36:2492-503. 10.1200\/JCO.2017.77.6880","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2019.06.009","article-title":"Neuroendocrine tumors of genitourinary tract: recent advances","volume":"42","author":"Shehabeldin AN","year":"2019","unstructured":"Shehabeldin AN, Ro JY. Neuroendocrine tumors of genitourinary tract: recent advances. Ann Diagn Pathol. 2019, 42:48-58. 10.1016\/j.anndiagpath.2019.06.009","journal-title":"Ann Diagn Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca V","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW, et al.. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019, 121:7-18. 10.1016\/j.ejca.2019.08.011","journal-title":"Eur J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102818","article-title":"Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives","volume":"130","author":"Akkus E","year":"2024","unstructured":"Akkus E, Arslan \u00c7, \u00dcr\u00fcn Y. Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives. Cancer Treat Rev. 2024, 130:102818. 10.1016\/j.ctrv.2024.102818","journal-title":"Cancer Treat Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio AM","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, et al.. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013, 19:3621-30. 10.1158\/1078-0432.CCR-12-3791","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522342-a-case-of-de-novo-neuroendocrine-prostate-cancer-presenting-with-elevated-carcinoembryonic-antigen-cea-levels","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:38:56Z","timestamp":1786747136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522342-a-case-of-de-novo-neuroendocrine-prostate-cancer-presenting-with-elevated-carcinoembryonic-antigen-cea-levels"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.114549","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}